TeloView^®

TeloView^® is the core of our proprietary technology and it consists of two parts, analytical software and a corresponding report designed for clinical decision making.

Our software was developed internally by Telo Genomics and then scaled and validated by CIMTEC, a respected Canadian imaging-software developer.

TeloView^® utilizes the 3-dimensional analysis of 6 key parameters generated from the telomeres of a single cell. Multiple cells from an individual patient are independently analyzed.

TeloView^®’s software generates a report for the clinician that contains important, actionable information including; the stage of a given disease, it’s rate of progression and how it will respond to therapy.
‍
TeloView^® is effective on any tissue type, but is focused on non-invasive applications
such as liquid biopsy (blood, urine, saliva etc.).
‍
Non-invasive sampling methods are fast, relatively inexpensive and reproducible compared to tissue biopsies and can be used more frequently for the monitoring of patients. It involves the collection of circulating tumor cells (CTC’s), circulating tumor DNA (ctDNA) or other informative marker cells.
‍
TeloView^® sits at the end of a multi-step process that gathers and presents target cells in a 3-dimensional format that can be analyzed to generate a TeloView_® report.

Sample Accession

Samples (from blood, urine, etc.) are inspected and assigned an ID

3D - Telomere
immuno-FISH

Specific labeling of telomeres and disease specific proteins with fluorescent tags

3D Image Acquisition

Acquires consecutive images at consecutive focal planes across the depth of the sample to build one 3D image

TeloView^®Analysis

1. # of Telomeres
2. Telomere lengths
3. Telomere aggregates
4. a:c Ratio
5. Nuclear volume
6. Position in nucleus

Personalized TeloView^®Lab Report

Personalized results that inform and guide treatment

Key Publications with Potential Clinical Relevance

Key publications of interest and with clinical relevance include Telo Genomics’ lead indication multiple myeloma, Alzheimer’s disease and prostate cancer.
‍
- Tabs contain synopses of the key publications
- Below are the original publications

A proof of concept study (Klewes et al., 2013) and validation study (Yu et al., 2019) showing the utility of TeloView® technology to stratify multiple myeloma patients
TeloView® technology for multiple myeloma can be conducted on liquid biopsy (blood samples) (Klewes et al., 2013)
TeloView® technology utility as a companion diagnostics tool that can potentially predict patient’s drug response (Kashton-Taylor et al., 2017)

Telomere Architecture, Quantified Using TeloView® Technology Correlates with Aggressiveness in Multiple Myeloma, Smouldering Myeloma and MGUS Patients
‍Aline Rangel-Pozzo, Sherif Louis, Hans Knecht & Sabine Mail. Cancers. 2021, 13(8), 1969

TeloView® Technology Identifies Smouldering Myeloma Patients with High Risk of Progression to Full Stage Multiple Myeloma..
Sherif Louis, Hans Knecht & Sabine Mai. Blood. 2020, 136 (Supplement 1):19-20.

Distinct nuclear organization of telomeres and centromeres in monoclonal gammopathy of undetermined significance and myeloma.
Yu PLI & Mai S et al. Cells 8, 723, 2019.

Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells.
Taylor-Kashton C & Mai S et al. XPO1 J Cell Physiol. 2016 Dec;231(12):2711-9.

3D nuclear telomere organization in multiple myeloma.
Klewes L & Mai S et al. Trans. Oncol. 2013 6(6): 749–756

A proof of concept study (Mathur et al., 2014) and a validation study (Garcia et al., 2017) showing the potential of TeloView® technology to stratify AD patients into their respective clinical disease stage

Quantitative 3D telomeric imaging of buccal cells reveals Alzheimer’s disease-specific signatures.
Garcia A & Mai S et al. J Alzheimer’s Dis. 2017;58(1):139145.

Three-dimensional quantitative imaging of telomeres in buccal cells identifies mild, moderate and severe Alzheimer patients. J of Alzheimer’s Disease.
Mathur S & Mai S et al. 2014 Jan 1;39(1):35-48.

With a 77% prediction power, TeloView® predicts intermediate risk PC patients who require clinical intervention (prostatectomy) versus patients who qualifies for active surveillance (Drachenberg et al., 2019)
TeloView® technology for PC can be conducted on liquid biopsies (circulating tumor cells isolated from blood samples) from all patient-risk groups of the disease (Adebayo et al., 2013, Awe et al., 2017)

Advancing risk assessment in intermediate risk prostate cancer patients.
Drachenberg D & Mai S et al. Cancers 11, 855, 2019

Filtration-based enrichment of circulating tumor cells from all prostate cancer risk groups.
Adebayo Awe J & Mai S et al. Urol Oncol. 2017 May;35(5):300309

3D telomeric analysis of isolated circulating tumor cells (CTCs) defines CTC subpopulations.
Awe JA & Mai S et al. Trans. Oncol. 2013 2013 Feb;6(1):51-65.

TeloView®